Related Experiment Video
Updated: Feb 12, 2026

Setup and Execution Of the Blindfolded Code Training Exercise
Published on: March 29, 2019
Lessons From LEADER - All-round Leadership
1Department of Endocrinology, Bharti Hospital, Karnal, India.
Abstract:
The large multinational, randomised, double-blind LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results - A Long Term Evaluation) trial recently reported the cardiovascular (CV) benefits achieved with liraglutide therapy in type 2 diabetes mellitus (T2DM). This editorial analyses the primary and secondary CV outcomes (CVO) results of the LEADER trial, and discusses the impact these will have on clinical practice of diabetes in specific, and medicine in general. It delves into the evolution of clinical and biochemical outcomes used in diabetes, and discusses the role of liraglutide in shaping future outcomes. The editorial describes the potential role of liraglutide in primary, secondary and tertiary prevention of CV disease (CVD), and suggests exaptation of this molecule for use in cardiology, nephrology and neurology.
Related Concept Videos
Groupthink
Transfer RNA Synthesis
Each of these chemical modifications is carried by a specific enzyme, post-transcription. All of these enzymes have unique base and site-specificity. Methylation, the most common chemical modification, is carried by at least nine different enzymes, with...
The Stanford Prison Experiment
Quantum Numbers
Self-Discrepancy Theory
The Sense of Self: Reflected Self-Appraisal and Social Comparison

